Researchers from Merck Healthcare KGaA Report Recent Findings in Antidiabetic Agents (Bioequivalence of Related Gelshieldr Sustained-release Formulations of Metformin: a Pooled Pharmacokinetic Analysis).

A recent study conducted by researchers from Merck Healthcare KGaA in Darmstadt, Germany, has found that the GelShieldR sustained-release formulation tablet of GlucophageR, a brand of metformin hydrochloride, is bioequivalent to the historic version marketed in 2000. The study evaluated the bioequivalence between the current round tablet from Europe and the historic oblong tablet from the United States. The results showed that there was bioequivalence between the two formulations in terms of pharmacokinetic parameters. The researchers concluded that the efficacy and safety of GlucophageR XR can be claimed along the evolution of the formulation. [Extracted from the article]